1. Scrip
  2. >>Business
  3. >>Financing

VC Fundraising Fell In Q4 But There Are Glimmers Of Hope For 2024

Quality Of Top Five Financings Bodes Well

 
• By Mandy Jackson

Evaluate’s fourth quarter data show that biopharma venture capital fundraising fell from $4.28bn in in Q3, but there was a rise in smaller deals and financial market conditions are poised for a turnaround.

Internet, business, Technology and network concept. Venture capital. Investor capital.
Q4 VC funding fell from Q3, but smaller deals rebounded • Source: Shutterstock

The slowdown in financings across the biopharmaceutical spectrum hit private and public companies alike in 2023 and the latest venture capital fundraising data from Evaluate indicate that last year did not end on a high note. However, the numbers mostly show the industry holding steady as it braces for a potential upswing in 2024 based on signs that financial market conditions may be easing.

Key Takeaways

  • Venture capital fundraising by biopharma companies declined from $4.28bn in Q3 to $3.71bn in Q4, according to Evaluate.

Evaluate tallied $3.71bn in venture capital raised globally by 86 drug developers during the fourth quarter, down from $4.28bn raised...

More from Financing

More from Business

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Finance Watch: Insmed Cashes In On Positive Data With $750m Offering

 
• By Mandy Jackson

Public Company Edition: Insmed raised $750m after reporting positive Phase IIb data in PAH, Cogent accessed up to $400m in new debt, Kelun-Biotech netted $250m in a placement of shares and ADC revealed a $100m private placement. In strategic updates, Recursion cut 20% of its jobs.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.